DK2801360T3 - Use of nicotine in the treatment of post-traumatic haemorrhage in humans - Google Patents

Use of nicotine in the treatment of post-traumatic haemorrhage in humans Download PDF

Info

Publication number
DK2801360T3
DK2801360T3 DK14170573.1T DK14170573T DK2801360T3 DK 2801360 T3 DK2801360 T3 DK 2801360T3 DK 14170573 T DK14170573 T DK 14170573T DK 2801360 T3 DK2801360 T3 DK 2801360T3
Authority
DK
Denmark
Prior art keywords
msh
ischemia
nicotine
renal
trauma
Prior art date
Application number
DK14170573.1T
Other languages
Danish (da)
English (en)
Inventor
Herrera Arturo Solis
Original Assignee
Herrera Arturo Solis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2801360(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Herrera Arturo Solis filed Critical Herrera Arturo Solis
Application granted granted Critical
Publication of DK2801360T3 publication Critical patent/DK2801360T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
DK14170573.1T 2006-05-08 2006-05-08 Use of nicotine in the treatment of post-traumatic haemorrhage in humans DK2801360T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06747531A EP2027860A1 (en) 2006-05-08 2006-05-08 The use of nicotine, analogues thereof, precursors thereof or derivatives thereof in the treatment of various pathological processes capable of improvement with alpha-msh administered in prophylactic or therapeutic form
EP14170573.1A EP2801360B1 (en) 2006-05-08 2006-05-08 The use of nicotine for the treatment of post traumatic bleeding in humans
PCT/MX2006/000031 WO2007129879A1 (es) 2006-05-08 2006-05-08 EL USO DE LA NICOTINA, SUS ANÁLOGOS, SUS PRECURSORES O SUS DERIVADOS EN EL TRATAMIENTO DE DIVERSOS PROCESOS PATOLÓGICOS SUSCEPTIBLES DE MEJORAR CON α-MSH ADMINISTRADA EN FORMA PROFILÁCTICA O TERAPÉUTICA.

Publications (1)

Publication Number Publication Date
DK2801360T3 true DK2801360T3 (en) 2018-07-23

Family

ID=38667940

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14170573.1T DK2801360T3 (en) 2006-05-08 2006-05-08 Use of nicotine in the treatment of post-traumatic haemorrhage in humans

Country Status (13)

Country Link
US (4) US20090197921A1 (cg-RX-API-DMAC7.html)
EP (4) EP2801359A3 (cg-RX-API-DMAC7.html)
JP (1) JP2009536193A (cg-RX-API-DMAC7.html)
KR (1) KR20130116374A (cg-RX-API-DMAC7.html)
CN (1) CN101437515B (cg-RX-API-DMAC7.html)
AU (1) AU2006343439B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0621650A2 (cg-RX-API-DMAC7.html)
CA (1) CA2651580C (cg-RX-API-DMAC7.html)
DK (1) DK2801360T3 (cg-RX-API-DMAC7.html)
ES (1) ES2683323T3 (cg-RX-API-DMAC7.html)
MX (1) MX2008011473A (cg-RX-API-DMAC7.html)
NZ (1) NZ572366A (cg-RX-API-DMAC7.html)
WO (1) WO2007129879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20110206642A1 (en) * 2009-10-15 2011-08-25 Cohava Gelber Preventing obesity-related metabolic syndrome with melagonesis
US9668969B1 (en) 2012-02-22 2017-06-06 Arturo Solis Herrera Methods of using QIAPINE
KR20170043655A (ko) 2014-09-09 2017-04-21 아르투로 솔리스 헤레라 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
WO2017178897A2 (en) * 2016-04-12 2017-10-19 Arturo Solis Herrera Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
LU101520B1 (en) * 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
CA2560756A1 (en) * 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Methods and devices for reducing bleed time using vagus nerve stimulation

Also Published As

Publication number Publication date
US20120270907A1 (en) 2012-10-25
CN101437515B (zh) 2016-04-20
EP2801360A2 (en) 2014-11-12
EP2801358A3 (en) 2015-03-04
EP2801359A3 (en) 2015-05-06
US20090197921A1 (en) 2009-08-06
MX2008011473A (es) 2008-09-24
EP2801360A3 (en) 2015-03-04
CA2651580C (en) 2016-01-19
EP2801358A2 (en) 2014-11-12
US20160279116A1 (en) 2016-09-29
WO2007129879A1 (es) 2007-11-15
BRPI0621650A2 (pt) 2011-12-20
JP2009536193A (ja) 2009-10-08
ES2683323T3 (es) 2018-09-26
NZ572366A (en) 2012-02-24
US20160008347A1 (en) 2016-01-14
AU2006343439B2 (en) 2013-05-16
CA2651580A1 (en) 2007-11-15
EP2027860A1 (en) 2009-02-25
CN101437515A (zh) 2009-05-20
EP2801359A2 (en) 2014-11-12
KR20130116374A (ko) 2013-10-23
AU2006343439A1 (en) 2007-11-15
EP2801360B1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
US20090197921A1 (en) USE OF NICOTINE, ANALOGUES, THEREOF, PRECURSORS THEREOF OR DERIVATIVES THEROF IN THE TREATMENT OF VARIOUS PATHOLOGICAL PROCESSES CAPABLE OF IMPROVEMENT WITH a-MSH ADMINISTERED IN PROPHYLACTIC OR THERAPEUTIC FORM
JPH0196137A (ja) 真性糖尿病の治療
US20120232142A1 (en) Novel use of dimethylfumarate
CN113577083B (zh) 一种小分子化合物组合在制备预防和治疗视网膜损伤性疾病药物中的应用
Dick et al. Relaxation by vasoactive intestinal polypeptide in the gastric fundus of nitric oxide synthase‐deficient mice
RU2727142C2 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
US7423019B2 (en) Agent for inducing conversion of intestinal cells into insulin-producing cells and antidiabetic drug
CN110799189A (zh) 纯5-ht6受体拮抗剂的新用途
JPH02117698A (ja) 血管内皮細胞成長因子
WO2021208552A1 (zh) 甲状腺激素及其类似物在制备治疗α-地中海贫血中的应用
TW201800102A (zh) 用於提升clock基因、arntl基因、及/或per2基因之表現的苦瓜萃取物及其應用
RU2442584C2 (ru) ИСПОЛЬЗОВАНИЕ НИКОТИНА, ЕГО АНАЛОГОВ, ПРЕДШЕСТВЕННИКОВ И ПРОИЗВОДНЫХ ПРИ ЛЕЧЕНИИ РАЗЛИЧНЫХ ПАТОЛОГИЧЕСКИХ ПРОЦЕССОВ, ПОДДАЮЩИХСЯ ЛЕЧЕНИЮ, ПУТЕМ ВВЕДЕНИЯ α-MSH ДЛЯ ПРОФИЛАКТИЧЕСКИХ ИЛИ ТЕРАПЕВТИЧЕСКИХ ЦЕЛЕЙ
US9089554B2 (en) Composition comprising expression or activity regulators of AKAP12 for treating central nerve system diseases
KR20090006069A (ko) 예방적 또는 치료적 형태로 투여된 α-MSH를 사용하여 개선시킬 수 있는 다양한 병리 과정을 치료하기 위한 니코틴, 그의 유사체, 그의 전구체 또는 그의 유도체의 용도
KR102322102B1 (ko) 염증성 질환의 예방, 개선 또는 치료용 조성물
WO2017069376A1 (ko) IKKε 억제제를 함유하는 염증질환의 치료용 조성물
Meyhöfer Mastering the Heat: The Role of Thyroid Hormone Receptor α1 in Thermoregulation
CN121221609A (zh) 一种葡萄糖神经酰胺合成酶激活剂在制备预防和/或治疗焦虑的药物中的用途
Negri et al. Regulation of the JNK signaling pathway and pancreatic β-cell apoptosis by the scaffold protein islet-brain 2 (IB2)
Di Chen PhD et al. RASA1-driven cellular export of collagen IV is required for the development of lymphovenous and venous valves in mice
JPH09118622A (ja) 血圧降下剤
JPS61275225A (ja) 抗炎症剤